NCT01250236

Unknown

Effect of Brimonidine on Corneal Thickness

Augenarztpraxis Breisach Source

Other study identifiers

Sponsor study identifier

Grueb Klin CT

Study Type

observational

Estimated enrollment

10

Locations

1 country

Sites

1

Timeline

Study Start

December 2010

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2010

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 2010

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Brief Summary

Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is widely used in glaucoma treatment. Although it is known that it is quickly taken up by the cornea following topical administration and that the cornea has alpha-2 adrenoceptors there are only few studies available on the impact brimonidine has on the cornea. The aim of the study is to find out

1.whether topical administration of brimonidine results in interaction with corneal alpha-2 adrenoceptors in terms of an increase in corneal thickness and
2.whether there are any differences between the response corneal epithelium, stroma and endothelium show to alpha-2 adrenoceptor stimulation.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Estimated enrollment: 10 participants
Study completion date: December 2010
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
November 29, 2010
Actual (reported)
First Posted
November 30, 2010
Actual (reported)
Study Start
December 2010
Date type not reported
This date has not been verified as actual or estimated.
Primary Completion
December 2010
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
December 2010
Estimated (date passed)
This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated: December 3, 2010
Status Verified: December 2010
Last Update Submitted: December 2, 2010

Conditions

Impact of Brimonidine on the Cornea

Keywords

brimonidinealpha-2 adrenoceptorcorneacorneal thickness

Outcome Measures

Primary Outcomes (1)

corneal thickness
5 days

Secondary Outcomes (1)

intraocular pressure
5 days

Study Arms (2)

verum

brimonidine 0.1% eye drops twice daily

Drug: brimonidine 0.1%

placebo

sodium hyaluronate 1.8mg/ml eye drops twice daily

Drug: placebo

Interventions

brimonidine 0.1%Drug

brimonidine 0.1% eye drops twice daily

verum

placeboDrug

sodium hyaluronate 1.8mg/ml eye drops twice daily

placebo

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

consecutive

You may qualify if:

healthy, 18-99 years, normal ophthalmologic history, consent to participate in the study

You may not qualify if:

Sponsors & Collaborators

Augenarztpraxis Breisach
Otherlead

Study Sites (1)

Augenarztpraxis

Breisach, Baden-Wurttemberg, 79206, Germany

RECRUITING

Matthias Grueb, Priv. Doz. Dr.CONTACT004976677766 matthias.grueb@web.de

Matthias Grueb, Priv. Doz. Dr.PRINCIPAL INVESTIGATOR

MeSH Terms

Conditions

Corneal Diseases

Condition Hierarchy (Ancestors)

Eye Diseases

Study Officials

Matthias Grueb, Priv. Doz. Dr.
Augenarztpraxis Breisach
STUDY DIRECTOR

Central Study Contacts

Matthias Grueb, Priv. Doz. Dr.

CONTACT

004976677766 matthias.grueb@web.de

Study Design

Study Type: observational
Observational Model: CASE CONTROL
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER

Study Record Dates

First Submitted

November 29, 2010

First Posted

November 30, 2010

Study Start

December 2010

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2010

Estimated (date passed)

NCT00652483

Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Phase 3Completed

NCT01105065

Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma

Not ApplicableCompleted

NCT00168363

Safety and Efficacy of Brimonidine in Patients With Glaucoma or Ocular Hypertension

Phase 3Completed

NCT05480098

Brimonidine for Intraoperative Hemostasis

Phase 4Withdrawn

NCT02289352

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

Phase 3Completed

NCT07431476

Brimonidine 0.33% for Rosacea-Related Facial Erythema

Phase 4Completed

any serious medical or neurologic conditions and/or regular use of local or systemic medications

Contact the study team to confirm eligibility.

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Study Completion

December 2010

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Last Updated

December 3, 2010

Record last verified: 2010-12

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT01250236
Data provider: ClinicalTrials.gov
Source updated: 2010-12-03
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:36 UTC

Locations

DE(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Study Arms (2)

verum

placebo

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

Source record

Locations